| Time | Program | SPEAKER |
|---|---|---|
| 10:00 – 10:30 | Opening Ceremony | |
| 10:30 – 11:00 | Keynote Speech Future Strategies for K-Bio’s Global Advancement and Innovation Pathways for the Osong Bio Cluster | |
| 11:00 – 12:00 | Opening Panel Discussion The Future of Osong and the Global Bio·Health Leap: Innovation, Investment & Infrastructure | (Chair) Hanlim Moon, President, Korean Society for Clinical Pharmacology and Therapeutics Younghan Shin, Governor, Chungcheongbuk-do Province Jangsub Lee, Mayor, Cheongju City Yeonhee Lee, Member of the National Assembly |
| 12:00 – 13:30 | BREAK | |
| 13:30 – 14:10 | Plenary Session Ⅰ Evolving Regulatory Pathways for Early-Phase Clinical Trials of Biologics: Korea-Japan Collaboration in FIH Studies, Biosimilar Development, and Biomarker-Driven Approaches. | |
| 14:10 – 14:20 | BREAK | |
| 14:20 – 15:00 | Plenary Session Ⅱ AI-Driven and Digital Transformation in Clinical Trials: Accelerating Global Drug Development through Intelligent Data Platforms. | |
| 15:00 – 15:10 | BREAK | |
| 15:10 – 16:50 | Industry & Clinical Session | |
Talk 1 Cell and Gene Therapy: Current Landscape, Future Perspectives, and CHA Biotech’s R&D Strategy | ||
Talk 2 OHPAS™, PMT™, and Nexatecan™ Technologies for Enhanced ADC Efficacy and Safety | ||
Talk 3 From Platform to Pipeline: Translational Strategies for Developing 4-1BB Bispecific T-cell Engagers and Bispecific ADCs | ||
| Time | Program | SPEAKER |
|---|---|---|
| 10:00 – 13:30 | BREAK | |
| 13:30 – 16:30 | Workshop Session The Journey of Drug Development: From Drug Discovery to Phase 3 Clinical Trials Part ① 1. Long Journey of New Drug Development - Course introduction 2. War game for new drug development (Hands-on) Part ② Various clinical trials during new drug development: From Phase 1 to Phase 3 | |
| Time | Program | SPEAKER |
|---|---|---|
| 10:00 – 12:05 | Medicinal Chemistry & AI Discovery Session New Horizons in Medicinal Chemistry for Innovative Drug Discovery: Converging AI with New Modality. | |
Talk 1 Bridging Protein Structures and Chemical Space through AI and Molecular Simulations | ||
Talk 2 From Synthetic Methodology to Drug Discovery: A Journey in Medicinal Chemistry | ||
Talk 3 Harnessing Targeted Protein Degradation: Unlocking Undruggable Targets through GSPT1 Molecular Glue Degrader | ||
Talk 4 Development of Small-Molecule Immunomodulators | ||
| 12:05 – 14:00 | BREAK | |
| 14:00 – 16:30 | Policy & Regulatory Session Regulatory Science & Bio-Data Innovation: The Future of the Osong Bio Cluster | |
Talk 1 [Regional Strategy] Chungbuk NEXT Bio Industry Development Strategy | Yongil Lee, Director of Bio Policy Division, Chungcheongbuk-do Province | |
Talk 2 Support Policies for the Globalization of K-Bio | Kyungmoo Heo, Pharmaceutical Affairs Officer, Biopharmaceutical Policy Division | |
Talk 3 Strategy for Construction of AI-Driven de novo Antibody Design Platform using High-Quality Antigen-Antibody Data | ||
Talk 4 Trends and Challenges in Building Bio AI Services for Korean Public Institutions: Lessons from Real-World Cases | ||
Talk 5 [Global Strategy] Regulatory Innovation and Bio Cluster Competitiveness from a Global Bio Company's Perspective | Kwiman Kang, Executive Director and Head of Medical Division, Product Development Division, Celltrion | |
| Time | Program | SPEAKER |
|---|---|---|
| 10:25 – 12:15 | Investment Session Bio & Healthcare Investment Trends and Funding & Scale-up Strategies | |
Talk 1 Fundraising and Global Growth Strategies for AI Healthcare Startups | ||
Talk 2 2026 K-Bio: Opportunities and Challenges | ||
Talk 3 The Formula for Tech Startup Success: Technology, Investment, and Commercialization | ||
Talk 4 Know Yourself, Know Your Investor: IR Strategies for Successful Fundraising | ||
| 12:15 – 14:00 | BREAK | |
| 14:00 – 16:40 | Bio Beauty Science Session Go to the Side Events · Bio Beauty Science Session page → Bio Material Innovation and Cosmeceutical Science: Global Commercialization Strategies for K-Beauty and Wellness Food | |
• The detailed program is subject to change depending on operational circumstances.